Financial reports
10-K
2023 FY
Annual report
27 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
10-K
2022 FY
Annual report
16 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
14 Mar 22
Current reports
8-K
Other Events
5 Mar 24
8-K
Tarsus Announces Proposed $100.0 Million Public Offering
1 Mar 24
8-K
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
26 Feb 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
8-K
Leading the Way in Category Creation J A N U A R Y 2 0 2 4 Sulma, an XDEMVY® Patient
8 Jan 24
8-K
Ersa Phase 2a Study Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Mites Topline Data Presentation December 2023
11 Dec 23
8-K
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
9 Nov 23
8-K
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
10 Aug 23
8-K
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of
2 Aug 23
8-K
Other Events
31 Jul 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
29 Feb 24
S-3ASR
Automatic shelf registration
29 Feb 24
S-8
Registration of securities for employees
27 Feb 24
S-3
Shelf registration
9 Nov 23
424B5
Prospectus supplement for primary offering
2 Aug 23
424B5
Prospectus supplement for primary offering
31 Jul 23
S-8
Registration of securities for employees
17 Mar 23
424B5
Prospectus supplement for primary offering
3 May 22
FWP
Free writing prospectus
3 May 22
Other
EFFECT
Notice of effectiveness
22 Nov 23
CORRESP
Correspondence with SEC
17 Nov 23
UPLOAD
Letter from SEC
16 Nov 23
UPLOAD
Letter from SEC
18 Apr 23
CORRESP
Correspondence with SEC
13 Apr 23
UPLOAD
Letter from SEC
30 Mar 23
EFFECT
Notice of effectiveness
8 Nov 21
CORRESP
Correspondence with SEC
3 Nov 21
UPLOAD
Letter from SEC
3 Nov 21
EFFECT
Notice of effectiveness
16 Oct 20
Ownership
4
Aziz Mottiwala
19 Mar 24
4
Bryan Wahl
19 Mar 24
4
Bobak R. Azamian
19 Mar 24
4
Dianne C. Whitfield
19 Mar 24
4
Seshadri Neervannan
19 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
18 Mar 24
144
Notice of proposed sale of securities
18 Mar 24